7.48 +0.02 (0.27%)
After hours: 4:16PM EDT
|Bid||7.45 x 42300|
|Ask||7.46 x 38800|
|Day's Range||7.42 - 7.66|
|52 Week Range||4.05 - 12.52|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||34.54|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Many North Americans have turned to CBD products to ease living with conditions like anxiety, depression, and joint pains. But the medical community is still uncertain what effects CBD products have on those that use them. Green Roads CEO Laura Fuentes joins Yahoo Finance's Julie Hyman, Adam Shapiro, and Teucrium Funds Founder Sal Gilbertie to discuss her company's path to promoting health and wellness through the sale of CBD products
As part of the agreement, mixed martial arts organization Bellator MMA will give cbdMD exclusive branding rights inside the Bellator cage. CbdMD president Caryn Dunayer said in the press release the partnership will position the company to "educate athletes and fans" about the multiple benefits of CBD. Need more cannabis news?
As the cannabis sector matures and continues to open up with the edibles launch on the way this year, we just got through another round of earnings. This past quarters earnings were nothing pretty for most companies and we saw a lot of the large-cap companies fall short of analyst estimates — namely Aurora Cannabis (ACB), Canopy Growth (CGC), and Canntrust (CTST). Losses mounted for many cannabis companies focused on expansion, technology, and future market share. Canopy Growth lost over 300 million CA dollars in their last quarter due to higher employee compensation and a paper charge regarding the company’s convertible debt. These losses highlight some of the growing pains that these new companies have to go through in such a fast-changing industry. Prior to earnings season this quarter we saw a massive bull run for the majority of the large-cap cannabis stocks up until about the end of March.What Changed in March?In March we saw most of the large-cap cannabis stock prices peak relative to the broader indexes, using the S&P 500 as an example. In this chart below we compare Aurora Cannabis, Canopy Growth Corporation, Canntrust and HMMJ Horizons Marijuana Life Sciences ETF. Using this ETF is a great way to gauge the large-cap index as a whole. We can see that the cannabis sector peaked in March, hitting its highest point around March 19th.What I think happened in March was that investors started to take a look at their portfolios. They were noticing that the cannabis sector had outperformed the S&P 500 by over 3x at that point (HMMJ sitting up 60+% meanwhile the S&P had gained roughly 20%). Investors started to shift their money into more defensive names, as they felt that a pullback was imminent after such a strong rally in the markets. This turned out to be true as the cannabis sector declined from March and only accelerated after companies released one disappointing quarter after another. That massive three-month bull run was enticing enough for investors to start selling their cannabis stocks before earnings and if you did so, you were very fortunate. As a long term investor, you need to be able to have a strong stomach for volatility within the cannabis sector, but it still never fails to amuse me how the business cycle works, along with understanding investor psychology.What Happens Next?Now that the post-legalization hype has subsided and the markets have already had the opportunity to rally, we are seeing many of our most popular cannabis stocks trading at much lower valuations than just a few short months ago. Just because the stocks are cheap, does not mean that they will magically rise once again without a reason. Personally, I think there are a few things that need to happen for a company to buck the trend, and it starts with proving what they said they were going to do. Many companies made huge promises pre-legalization which drove valuations to historic highs, only to see the stocks crash due to overhype and deteriorating market conditions. Now we need to see strong execution within their business model coupled with a focus on market share and international expansion. As investors, we are always looking years down the road, and the companies that are set up to capitalize on markets outside of Canada will be the most profitable and sustainable companies. For the near term, I want to see companies focusing on the CBD market in the U.S. along with pending federal legalization. Along with this very profitable potential opportunity, I feel that the companies who focus on higher margin products and can dominate the retail and branding aspect of the business will see short-term profitability. For me, it comes down to a two-pronged approach and the company that can perfect this combination will be the most successful in terms of profit along with share price appreciation.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here.Disclosure: The author is Long ACB, CTST Read more on the stocks mentioned: * Aurora Cannabis (ACB) Investors Seem to Be Missing the Latin American Opportunity * Market Delays Can Derail Aurora Cannabis (ACB) Stock * Canopy Growth (CGC) Continues to Struggle to Find its Identity * CannTrust: Even With Entry Into U.S. Market, Investors Must Remain Patient More recent articles from Smarter Analyst: * Last Minute Thought: Buy or Sell Micron (MU) Stock Before Q3’19 Earnings? * Canopy Growth (CGC) Stock: Buy the Dip or Pump the Brakes? * Canopy Growth (CGC): Recent Licence from Health Canada Ain't Going to Help the Stock * Micron (MU) Stock Remains a Longer-Term Value Play, Says Analyst Ahead of Earnings
Marijuana stocks have been a volatile but largely outperforming group in 2019. But an analyst warns that while some companies are living up to the hype, others have risen too far, too fast.
Aurora Cannabis is on track to be the one of the first big marijuana firms to turn a profit. That could come as soon as this quarter, a top pot analyst said.
Several Wall Street analysts have come out bullish on cannabis stocks in recent months, but one analyst said Monday that Aurora Cannabis Inc (NYSE: ACB ) is the clear top choice in the sector. The Analyst ...
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
U.S. stock futures are trading higher this morning.Heading into the open, futures on the Dow Jones Industrial Average are up 0.24%, and S&P 500 futures are higher by 0.21%. Nasdaq-100 futures have added 0.30%.In the options pits, call trading carried equities into the weekend, even as overall volume settled at above-average levels. Specifically, about 20.4 million calls and 16.9 million puts changed hands on the day.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe action at the CBOE mirrored the bullishness with the single-session equity put/call volume ratio closing near Thursday's lows at 0.53. At the same time, the 10-day moving average matched Thursday's close near 0.62.Options activity was a mixed bag on Wednesday (options traders zeroed in on analyst actions yesterday). Canopy Growth (NYSE:CGC) shares fell after a disappointing earnings report. Microsoft (NASDAQ:MSFT) finally succumbed to profit-taking after notching three record highs in a row. Netflix (NASDAQ:NFLX) rallied for its fifth day in a row on heavy volume.Let's take a closer look: Canopy Growth Corp (CGC)Last week's earnings report provided little help to Canopy Growth Corp's struggling stock price. By day's end, the Canadian-based Cannabis company slipped 8% to close near a new five-month low. Fellow pot stocks Cronos Group (NASDAQ:CRON) and Aurora Cannabis (NYSE:ACB) both fell in sympathy, though their losses were pared before the closing bell.For the fiscal 2019 fourth-quarter, Canopy saw revenue of CAD $94.1 million. The number inched past analyst estimates for CAD $93.7 million and reflected a 13% rise over last quarter's revenue. Despite the slight bump in sales, CGC reported a net loss of CAD $323.4 million or 98 cents per share.Friday's plunge landed CGC at the lower end of its multi-month trading range and places it on precarious footing heading into the new week. Until the stock can reclaim the high ground above resistance at $44.40, steer clear of bullish trades.On the options trading front, traders favored calls over puts on the session despite the thrashing. Total activity swelled to 404% of the average daily volume, with 115,508 contracts traded. Calls claimed 56% of the session's sum. * 7 Top S&P 500 Stocks of 2019 (So Far) Option premiums were pricing in a $2.95 or 7% gap on the news. That makes Friday's 8.1% drop slightly outside of expectations, marking a small win for volatility buyers ahead of the event. Microsoft (MSFT)Record highs continue to stack up for Microsoft. Last week, the software titan notched three all-time highs in a row before sellers finally stopped the advance on Friday. The snap-back from June 3rd's wrecking of the tech sector on government oversight concerns has been relentless. Since bottoming at $119.01, MSFT stock has powered higher by 15%.Volume reached a crescendo ahead of the weekend reflecting powerful accumulation beneath the surface. While the overbought conditions certainly warrant some backing and filling, there's no doubt institutions highly favor Microsoft right now.On the options trading front, calls ruled the roost. Activity popped to 131% of the average daily volume, with 206,455 total contracts traded; 62% of the trading came from call options alone.Implied volatility drifted to 23% or the 18th percentile of its one-year range. Premiums are now pricing in daily moves of $1.99 or 1.5%. Netflix (NFLX)The news was light on Friday for Netflix, but that didn't stop buyers from sending the streaming media giant higher for the fifth consecutive day. Last week's rally returns NFLX stock to within striking distance of an upside breakout. What began as a well-deserved pause after a red-hot rally to kick-off 2019 has morphed into a tight five-month trading range.Given the utter lack of directional movement, volatility measures like the Bollinger bands have narrowed considerably on the weekly time frame. At some point, the stalemate will end, and if history is any indication, the breakout should bring fireworks. The two levels to watch for resolution are $386 and $340. * 10 Best High-Growth Stocks to Buy for Young Investors On the options trading front, calls were the clear victor in Friday's popularity contest. Total activity ramped to 156% of the average daily volume, with 214,525 contracts traded; 63% of the trading came from call options alone.Implied volatility held steady on the session at 45% or the 41st percentile of its one-year range. Premiums are pricing in daily moves of $10.38 or 2.8%.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Telecom Stocks to Set on Speed Dial * 6 Stocks to Sell in the Back Half of 2019 * 7 Top S&P 500 Stocks of 2019 (So Far) Compare Brokers The post Monday's Vital Data: Canopy Growth Corp, Microsoft and Netflix appeared first on InvestorPlace.
Some of those may have gained their wealth through the Evolve Marijuana ETF (TSE:SEED) (OTC:EVVLF), which, in the last year, has delivered the best performance among all cannabis ETFs. Need more cannabis news? Evolve launched SEED on the Toronto Stock Exchange roughly 14 months ago.
The hottest marijuana stock in early 2019 was Cronos Group (NASDAQ:CRON). CRON stock rallied tremendously in early 2019 after the company scored a multi-billion dollar investment from global tobacco giant Altria (NYSE:MO).That investment put Cronos stock in unique company; the only other cannabis producer to score such an investment thus far is Canopy Growth (NYSE:CGC), and CGC, with a a $15 billion market cap, is widely considered the 800-pound gorilla of the cannabis world. In late 2018, Cronos stock had a $2 billion market cap.So the owners of CRON stock were euphoric about the Altria investment. They took it as a sign that Cronos now had the necessary firepower and resources to become a very big and important player in the cannabis market. Consequently, CRON stock rose from $10 in late 2018 to $25 by early March 2019.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Top S&P 500 Stocks of 2019 (So Far) But Cronos hasn't delivered on the hype. Instead, the company reported subpar early 2019 numbers which basically affirmed that Cronos isn't gaining share like investors had expected it to. As a result, CRON stock has fallen over the past few months. Today, its shares trade hands for about $16.The problem is that CRON stock is still far more richly valued than all of its peers. Thus, the stock price still indicates that the company will start generating strong growth in the foreseeable future. But current trends imply that such a rebound is unlikely to materialize.So Cronos stock should be avoided until CRON's higher growth does materialize because right now CRON offers too much risk and not enough reward. Cronos Stock Is Still Overvalued Relative to Its PeersAlthough CRON stock presently trades almost 40% off its 2019 highs, the stock is still overvalued relative to its cannabis peers. Further, there doesn't seem to be any good reason for the premium valuation of Cronos Group stock.Cronos has a market cap of $5.2 billion. The company sold just over 1,100 kilograms of cannabis last quarter. That means each kilogram of cannabis sold last quarter by Cronos is being valued by the market at roughly $4.7 million. That number ranges between $800,000 and $1.5 million for the three other big players in the Canadian cannabis market - Canopy, Aurora (NYSE:ACB), and Tilray (NASDAQ:TLRY) . Those three companies are trading at a average valuation of $1.3 million. per kilogram Thus, on a per-kilogram basis, the valuation of CRON stock is 260% higher than its peers.Why is Cronos stock getting a premium valuation? It has nothing to do with size. Cronos is much smaller than Canopy, Aurora, and Tilray. It also has nothing to do with growth. Last quarter, Cronos reported the slowest year-over-year revenue growth in the group. Nor does it have anything to do with U.S. market expansion, as Cronos hasn't announced anything too special on that front, while Canopy looks positioned to dominate the U.S. market with its Acreage acquisition.CRON stock has a premium valuation because of the $1.8 billion investment it received from Altria. But CRON stock's enterprise-value-to-expected-2020-sales multiple is around 25, versus an average of 15 for CGC, ACB, and TLRY.That $1.8 billion of cash could fuel acquisitions, expansions, and stronger growth. But that isn't happening yet. Until it does happen, CRON stock simply appears overvalued relative to its peers. CRON's Long-Term Fundamentals Don't Support Its Current ValuationThe bigger problem with Cronos stock is that it appears overvalued relative to its long-term growth prospects.Cronos is a small player in the Canadian cannabis market. In the fourth quarter of 2018, the sales of the legal Canadian cannabis market were worth around $150 million. Cronos reported revenue in that same quarter of roughly $4.2 million. Thus, Cronos commanded market share of about 3%. Given analysts' consensus projections regarding Cronos' sales and the Canadian cannabis market, it looks like most experts expect Cronos' market share to remain about 3% for the foreseeable future.On a global scale, that market share will assuredly come down as more competitors enter the cannabis sector. Thus, CRON's longer term market share in the $200 billion global cannabis market could be about 2%. That implies long-term revenue potential of $4 billion. Gross margins in the industry should hover around 55%, which is roughly where alcoholic beverage makers' gross margins stand today. CRON's operating spending rates should fall as it grows and will likely moderate around 30%. Thus, its longer term operating margins could be 25%. Assuming it generates $4 billion of revenue, it should have $1 billion of operating profit.After taking out 20% for taxes, its net profit would be $800 million. Based on a market-average 16 multiple, the long-term valuation target for Cronos stock is $12.8 billion.That will all take a long time to occur. Most industry insiders and analysts expect its growth to play out over 10 to 15 years. At the midpoint, that's about 12.5 years. After discounting that $12.8 billion valuation target back by 10% per year over 12.5 years, the present valuation target for Cronos stock comes out to less than $4 billion.CRON stock has a market cap above $5 billion today. Thus, until this company uses the $1.8 billion on its balance sheet to supercharge its growth and boost its growth outlook, CRON stock looks overvalued today. The Bottom Line on CRON StockThere is a valid argument for why CRON stock should be worth a lot more than it is today. But that argument relies on Cronos doing something it hasn't done yet: using the $1.8 billion on its balance sheet to materially gain market share in Canada and lay the groundwork for higher share in international markets.Until that happens, CRON stock will remain a "high risk, low reward" name, meaning that Cronos Group stock is best avoided for the foreseeable future.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Telecom Stocks to Set on Speed Dial * 6 Stocks to Sell in the Back Half of 2019 * 7 Top S&P 500 Stocks of 2019 (So Far) Compare Brokers The post Why Cronos Group Stock Still Looks Overvalued appeared first on InvestorPlace.
Cannabis stocks fell on Friday, led by Canopy Growth Corp., after the biggest company in the sector measured by market cap reported an unexpected decline in recreational pot sales in Canada in the fourth quarter from the previous one.
After Canopy Growth shares tanked 8% following disappointing earnings, CEO Bruce Linton said he thinks the company will become a leader the CBD market.
Being a landlord might not seem exciting, but rapidly rising dividends should get everyone's attention.
With the markets near all-time highs, there has been a nice rally in cannabis stocks, but Aurora Cannabis (NYSE:ACB) seems to have missed the memo. ACB stock has been languishing.Source: Shutterstock During the past couple weeks, Tilray (NASDAQ:TLRY) has logged a return of 32% while Cronos Group (NASDAQ:CRON) is up about 17% and Canopy Growth (NYSE:CGC) has gained 11%.Unfortunately, ACB stock has been in an extended downtrend, going from $10 in March to $7.48.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor the year so far Aurora Cannabis stock is still up an impressive 43%. When it comes to cannabis stocks, there is usually quite a bit of volatility and this is not likely to change any time soon. * 6 Stocks Ready to Bounce on a Trade Deal The Pros And Cons of ACB StockThe bearishness with ACB has been the result of various factors. Although, perhaps the most important is the string of disappointing earnings reports. Note that the Canadian market has proven more difficult with the transitional to legalized marijuana. There have been challenges with the supply chain and retail expansion. What's more, black market sources have remained a persistent issue.But hey, such growing pains should be no surprise. If anything, the recent weakness does make ACB stock look relatively attractive. Consider that the consensus price target is $14.27, which implies 91% upside from current levels.So what are some of the catalysts to get ACB stock back on track? Well, first of all, the company is a top producer in the Canadian market. During the latest quarter, the production nearly doubled to 15,000 kilograms. But with the acquisition of MedReleaf and a myriad of other investments, the potential annual capacity is a hefty 570,000 kilograms.The early experience in the Canadian market is crucial. Aurora is building a solid infrastructure, which will allow for economies of scale. This make it so the company can better compete as cannabis becomes more commoditized in the Canadian market. In fact, Aurora is already becoming a streamlined low-cost provider.But another key - especially for the long haul - is the medical business. The pipeline includes 40 in-process and completed clinical trials and case studies. There has also been continued growth in the patient base, which grew by 5% in 77,136 in the latest quarter. Other Opportunities for ACB StockAnother important development is a recent partnership with the Ultimate Fighting Championship (UFC), which is the world's largest martial arts organization. The agreement calls for an exclusive multi-year focus on clinical research using Cannabidiol (CBD), which is the compound in the cannabis sativa plant that does not produce a high. In other words, there is much potential for breakthroughs with new treatments.With the passage of the Farm bill, the CBD opportunity in the US looks promising and should be a strong catalyst for growth. During the latest earnings call, Aurora chief corporate officerCam Battley had the following to say:"We are well positioned to pursue multiple angles through our deep research and product development capabilities, our regulatory expertise as well as our extensive global hemp infrastructure which we intend to expand through acquiring the shares in HempCo, not already owned by Aurora. CBD for both medical and wellness applications has incredible potential and we intend to fully leverage our capabilities, our infrastructure and our partnership potential to maximize shareholder value creation." Bottom Line on ACB StockIn mid-May, Aurora brought on board as a strategic advisor Nelson Peltz, who is the CEO of Trian Fund Management. He has decades of experience with consumer markets, with investments in companies like PepsiCo (NASDAQ:PEP), Keurig Dr Pepper (NYSE:KDP), Procter & Gamble (NYSE:PG) and Mondelez (NASDAQ:MDLZ).Peltz's involvement is a strong validator. He should also be essential in finding strategic partners.Of course, even with the advantages, ACB stock still has lots of risks. But for investors looking for an interesting cannabis play, this one definitely is worth considering.Tom Taulli is the author of the upcoming book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal Compare Brokers The post ACB Stock Is a Buy Because Aurora Cannabis Won't Get Left in the Dust appeared first on InvestorPlace.
Investors, meet Akerna (NASDAQ:KERN), the newest marijuana stock to hit the market. Akerna is fundamentally different from many other marijuana stocks in two important ways. One, it's a U.S. company, whereas most pot stocks are Canadian ventures. Secondly, Akerna isn't a cannabis producer; it's a cannabis-technology company.Given those novelties, investors have rushed into KERN stock to gain a different type of exposure to the continuous-growth cannabis market. That's why KERN stock has essentially tripled over the past two days.With that in mind, let's now rewind a bit. The legal cannabis industry is poised to grow more quickly than most other markets over the next decade. Investors want exposure to that market. Right now, because we are in the top of the first inning of the cannabis sector's growth, investors' potential exposure to the legal cannabis industry is largely limited to Canadian cannabis producers like Canopy Growth (NYSE:CGC), Cronos (NASDAQ:CRON), Aurora (NYSE:ACB), and Tilray (NASDAQ:TLRY). Simply put, the biggest players in the cannabis space are producers, and pot still isn't legal in all of the U.S.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 Against that backdrop, Akerna's plunge into the public market is very interesting. A U.S.-based, cannabis technology company, KERN is the first of its kind to go public. And, because investors desperately want diverse exposure to the cannabis market, KERN stock has been a home-run hit ever since making its Wall Street debut.How did Akerna make it to the public market? Will the hype of KERN stock continue? Most importantly, is Akerna stock worth buying today? Let's answer those questions and more by taking a deep look at KERN stock. What Does Akerna Do?Akerna is a very interesting company that uses big data and technology to develop products for cannabis producers.At present, Akerna is supported by two major businesses. One of those businesses is seed-to-sale technology, which allows regulators and government agencies to track cannabis products from their cultivation to their final sale. This is a very important technology. In fact, it's necessary. Seed-to-sale tracking is required by states such as Washington and California and will likely be mandatory for the global cannabis industry.KERN's other meaningful business is broadly dubbed enterprise resource planning, which essentially involves selling big-data-focused software to cannabis producers and pot-store operators. The software is supposed to help players in the cannabis industry better understand their market and customers, as well as reduce expenses, maximize profit, improve customer relationships, and increase yield.Overall, then, Akerna is a cannabis-tech company which sells important technology solutions to cannabis industry regulators, cannabis producers, and retail cannabis companies. KERN hopes to become the technology backbone of the entire cannabis industry.It's already well on its way to that goal. Akerna's systems are used in 29 of the 33 U.S. states in which cannabis is legal. How Did Akerna Get Here?As mentioned earlier, KERN stock is the first of its kind to go public. Not only is KERN a cannabis-tech company, but it's a U.S.-based cannabis-tech company.KERN stock plunged into the public market through a smart merger and some savvy legal maneuvers.The core of Akerna is MJ Freeway, which is a U.S. technology company that provides the cannabis software solutions described earlier. Importantly, MJ Freeway isn't a cannabis company. It's a cannabis technology company. Because MJ Freeway doesn't deal directly with marijuana, it was able to sidestep the legality question and go public with less complications than cannabis producers.Further, MJ Freeway skipped the whole lengthy IPO process. Instead, MJ Freeway merged with a special purpose acquisition company (dubbed SPAC in Wall Street lingo) that was already public. That SPAC was MTech Acquisition. Thus, through MJ Freeway's merger with MTech Acquisition, the IPO cleared all the legal hurdles, and the combined entity was dubbed Akerna.That happened on June 17. Ever since, KERN stock has essentially tripled. Where Is Akerna Going Next?KERN stock has been a huge hit on Wall Street, mostly because the stock offers investors unique exposure to a non-cyclical growth market, and is supported by a speculative but enticing long-term growth narrative which, in a best case scenario, ends with Akerna being the technology behemoth underlying the $200 billion-plus global cannabis industry.Does that mean it's time to buy KERN stock?No. KERN stock has a lot of potential. But all that potential isn't very certain to materialize and it lacks tangibility. The company reported just $10 million of revenue last year. That's next-to-nothing. To bridge the gap between that $10 million 2018 revenue base and a potential billion dollar revenue base in a decade, a lot needs to happen.At this point in time, that growth isn't visible. It's simply too early to declare Akerna stock a long-term winner in the cannabis-tech space.Over the next several months, KERN will be given the opportunity to more convincingly prove its leadership position and cement itself as a long-term cannabis-tech winner, much like Canopy Growth did in 2018 in cannabis production. If that happens, KERN stock will become worth buying. But, until then, the sidelines are the safest and smartest place to hang out when it comes to Akerna stock. The Bottom Line on KERN StockKERN is exciting because, as a U.S.-based cannabis-tech stock, it's the first of its kind. This novelty is what has propelled KERN stock to a 200% gain in just a few trading days.The long-term bull thesis on KERN stock is promising. But it also lacks visibility and tangibility, meaning that it's still too early to tell whether or not Akerna will turn into a cannabis-tech giant or a bust. As a result, until KERN's outlook becomes more visible and tangible, KERN stock should be avoided.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 * 5 Boring Stocks to Buy This Summer * 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits Compare Brokers The post Akerna Stock Offers Investors a New Way to Play the Cannabis Craze appeared first on InvestorPlace.
Aurora said it will produce new, high-quality products for sale in the Canadian market. Ahead of the product launch, the cannabis company secured supply agreements with cannabis consumer technology brand PAX Labs. The company also established new production hubs across the country to provide centralized production, packaging, logistics and distribution capabilities.
EDMONTON, June 21, 2019 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (ACB) (ACB), the Canadian company defining the future of cannabis worldwide, today announced its plans for the highly-anticipated expansion of the consumer cannabis market into vapes, concentrates, and edibles.